TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas (NCT07082803)
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (11 items) and avoid the listed exclusions (8 items).
Location: Stanford Medicine Cancer Center — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Participants must not have current central nervous system (CNS) involvement. Participants with past history of CNS involvement of lymphoma must have had CNS disease fully treated with no evidence of recurrence within 12 months.
- Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days prior to the start of the study.
- Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.
- Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
- Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
- Pregnant or lactating.
- Conditions that could affect drug absorption.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (14 Sites)
- Stanford Medicine Cancer Center — Palo Alto, California
- The START Center for Cancer Care - Midwest — Grand Rapids, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medicine - New York Presbyterian Hospital — New York, New York
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Macquarie University Hospital — Macquarie Park, New South Wales
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Cabrini Health — Malvern, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Linear Clinical Research — Perth, Western Australia
- BC Cancer - Vancouver — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (857) 228-0050
Email: clinicaloperations@treeline.bio
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Aurora, Colorado
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy — Salt Lake City, Utah
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
- Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma — Rochester, Minnesota
- A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
Explore by condition: All Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.